-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $20

Benzinga·03/13/2025 12:04:55
Listen to the news
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the price target from $25 to $20.